InvestorsHub Logo
Followers 48
Posts 2673
Boards Moderated 0
Alias Born 12/19/2015

Re: None

Sunday, 01/01/2023 9:44:16 AM

Sunday, January 01, 2023 9:44:16 AM

Post# of 705010
Once approved (which will occur in 2023) the low end of the valuation spectrum is $21 Billion. Given that the tech is applicable to all solid tumor cancers and there are no negative side effects the high end of the spectrum is truly mind blowing.

Source: https://www.reuters.com/article/us-immunomedics-m-a-gilead-sciences/gilead-bolsters-cancer-portfolio-with-21-billion-acquisition-of-immunomedics-idUSKBN2640V8
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News